📊 CEROW Key Takeaways
Investment Thesis
Cero Therapeutics is a pre-revenue biotech company in severe financial distress with negative stockholders' equity of -4.5M, indicating liabilities exceed assets. The company is burning cash at -1.5M annually with only 1.9M in cash reserves, providing less than 18 months of runway, while demonstrating a catastrophic ROA of -393.2% and inability to cover operating costs.
CEROW Strengths
- Recent improvement in net loss (26.5% YoY reduction)
- Moderate insider activity suggesting management confidence
- Biopharmaceutical sector offers potential for high returns if pipeline succeeds
CEROW Risks
- Negative stockholders' equity represents technical insolvency risk
- Insufficient cash runway (<18 months at current burn rate)
- Pre-revenue stage with no demonstrated commercial viability
- Extreme negative ROA indicates severe value destruction
- Liabilities exceed assets by 4.6M, creating balance sheet crisis
- Operating losses accelerating despite YoY improvement
- Critical liquidity crisis with current ratio of 0.30x
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Achievement of clinical development milestones
- Equity financing or capital raise announcements
- Operating expense management and cash runway extension
CEROW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CEROW Profitability Ratios
CEROW vs Healthcare Sector
How CERO THERAPEUTICS HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CEROW Balance Sheet & Liquidity
CEROW 5-Year Financial Trend
5-Year Trend Summary: CERO THERAPEUTICS HOLDINGS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1,248.64 indicates the company is currently unprofitable.
CEROW Growth Metrics (YoY)
CEROW Capital Allocation
CEROW SEC Filings
Access official SEC EDGAR filings for CERO THERAPEUTICS HOLDINGS, INC. (CIK: 0001870404)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CEROW
What is the AI rating for CEROW?
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CEROW's key strengths?
Recent improvement in net loss (26.5% YoY reduction). Moderate insider activity suggesting management confidence.
What are the risks of investing in CEROW?
Negative stockholders' equity represents technical insolvency risk. Insufficient cash runway (<18 months at current burn rate).
What is CEROW's revenue and growth?
CERO THERAPEUTICS HOLDINGS, INC. reported revenue of N/A.
Does CEROW pay dividends?
CERO THERAPEUTICS HOLDINGS, INC. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find CEROW SEC filings?
Official SEC filings for CERO THERAPEUTICS HOLDINGS, INC. (CIK: 0001870404) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CEROW's EPS?
CERO THERAPEUTICS HOLDINGS, INC. has a diluted EPS of $-72.94.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.